MYO · Insider Trading
Myomo Inc.
Every open-market purchase and sale reported by MYO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Harry Kovelman | Chief Medical Officer | Sell | −15,844 | −$20.14K |
| 2026-10-15 | Paul R Gudonis | Chief Executive Officer | A | +71,250 | — |
| 2026-10-15 | Harry Kovelman | Chief Medical Officer | A | +32,500 | — |
| 2026-10-15 | David A Henry | Chief Financial Officer | A | +51,250 | — |
| 2026-10-13 | David A Henry | Chief Financial Officer | MIXED | +3,139 | −$4.29K |
| 2026-10-13 | Paul R Gudonis | Chief Executive Officer | A | +8,363 | — |
| 2026-10-13 | Mary-Katherine Hale McClure | Chief Commericial Officer | A | +275,000 | — |
| 2026-09-14 | Harry Kovelman | Chief Medical Officer | Sell | −15,488 | −$19.68K |
| 2026-09-04 | Milton Mayo Morris | Director | Sell | −15,000 | −$21.15K |
| 2026-08-24 | Harry Kovelman | Chief Medical Officer | Sell | −17,500 | −$30.33K |
| 2026-08-21 | Harry Kovelman | Chief Medical Officer | Sell | −17,250 | −$29.90K |
| 2026-08-11 | Micah Mitchell | Chief Commercial Officer | MIXED | +36,850 | −$30.61K |
| 2026-08-11 | David A Henry | Chief Financial Officer | MIXED | +43,334 | −$35.94K |
| 2026-08-11 | Paul R Gudonis | Chief Executive Officer | A | +146,909 | — |
| 2026-08-11 | Harry Kovelman | Chief Medical Officer | MIXED | +32,692 | −$31.89K |
| 2026-07-13 | Paul R Gudonis | Chief Executive Officer | A | +10,454 | — |
| 2026-07-13 | David A Henry | Chief Financial Officer | MIXED | +2,674 | −$5.63K |
| 2026-06-26 | Thomas Aloysius Crowley Jr. | Director | A | +78,704 | — |
| 2026-06-26 | Joseph M. Manko Jr. | Director | A | +78,704 | — |
| 2026-06-26 | Heather C Getz | Director | A | +78,704 | — |
| 2026-06-26 | Milton Mayo Morris | Director | A | +78,704 | — |
| 2026-06-26 | William J Febbo | Director | A | +78,704 | — |
| 2026-06-26 | Thomas F Kirk | Director | A | +78,704 | — |
| 2026-06-12 | David A Henry | Chief Financial Officer | F | −10,969 | — |
| 2026-06-12 | Micah Mitchell | Chief Commercial Officer | F | −9,061 | −$10.87K |
| 2026-06-12 | Harry Kovelman | Chief Medical Officer | F | −10,442 | −$12.53K |
| 2026-06-09 | Micah Mitchell | Chief Commercial Officer | F | −6,529 | −$8.68K |
| 2026-06-09 | David A Henry | Chief Financial Officer | F | −10,050 | — |
| 2026-06-09 | Thomas F Kirk | Director | Buy | +40,002 | +$50.80K |
| 2026-06-09 | Harry Kovelman | Chief Medical Officer | F | −7,635 | −$10.15K |
| 2026-06-08 | Micah Mitchell | Chief Commercial Officer | Sell | −90,231 | −$77.69K |
| 2026-06-01 | Thomas F Kirk | Director | Buy | +25,000 | +$24.82K |
| 2026-05-28 | Harry Kovelman | Chief Medical Officer | Sell | −32,000 | −$32.24K |
| 2026-05-18 | Joseph M. Manko Jr. | Director | Buy | +201,197 | +$173.91K |
| 2026-05-18 | Thomas F Kirk | Director | Buy | +75,006 | +$68.24K |
| 2026-05-15 | Micah Mitchell | Chief Commercial Officer | Sell | −90,231 | −$77.69K |
| 2026-04-16 | William J Febbo | Director | A | +45,000 | — |
| 2026-04-14 | David A Henry | Chief Financial Officer | MIXED | +8,547 | −$2.81K |
| 2026-04-14 | Paul R Gudonis | Chief Executive Officer | A | +16,666 | — |
| 2026-04-14 | Paul R Gudonis | Chief Executive Officer | A | +19,395 | — |
| 2026-03-17 | Heather C Getz | Director | Buy | +20,000 | +$13.97K |
| 2026-03-16 | Thomas F Kirk | Director | Buy | +72,000 | +$51.11K |
| 2026-03-12 | Heather C Getz | Director | Buy | +70,000 | +$50.96K |
| 2026-01-14 | David A Henry | Chief Financial Officer | A | +8,727 | — |
| 2026-01-14 | Paul R Gudonis | Chief Executive Officer | A | +11,637 | — |
| 2025-11-24 | Thomas F Kirk | Director | Buy | +7,437 | +$5.35K |
| 2025-11-21 | Thomas Aloysius Crowley Jr. | Director | Buy | +4,385 | +$3.23K |
| 2025-09-11 | Paul R Gudonis | Chief Executive Officer | G | −10,000 | — |
| 2025-08-26 | Thomas F Kirk | Director | Buy | +50,000 | +$57.50K |
| 2025-08-19 | Thomas F Kirk | Director | Buy | +50,000 | +$55.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph M. Manko Jr. | Director | 2,388,479 | $2.87M |
| Paul R Gudonis | Chief Executive Officer | 1,514,292 | $1.82M |
| Thomas F Kirk | Director | 772,569 | $927.08K |
| David A Henry | Chief Financial Officer | 549,862 | $659.83K |
| Mary-Katherine Hale McClure | Chief Commericial Officer | 275,000 | $330.00K |
| Heather C Getz | Director | 210,458 | $252.55K |
| Milton Mayo Morris | Director | 208,391 | $250.07K |
| Thomas Aloysius Crowley Jr. | Director | 154,931 | $185.92K |
| Micah Mitchell | Chief Commercial Officer | 152,297 | $182.76K |
| William J Febbo | Director | 123,704 | $148.44K |
| Harry Kovelman | Chief Medical Officer | 122,389 | $146.87K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MYO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.